Pfizer Inc. (NYSE:PFE) Stock Holdings Raised by Barnett & Company Inc.

Barnett & Company Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 5.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 213,625 shares of the biopharmaceutical company’s stock after purchasing an additional 11,970 shares during the quarter. Pfizer accounts for about 4.1% of Barnett & Company Inc.’s holdings, making the stock its 7th largest holding. Barnett & Company Inc.’s holdings in Pfizer were worth $6,182,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of PFE. Olistico Wealth LLC bought a new position in Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $29,000. Quarry LP bought a new position in shares of Pfizer in the second quarter worth approximately $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer in the second quarter worth $34,000. Finally, ESL Trust Services LLC bought a new stake in Pfizer during the 1st quarter valued at $37,000. 68.36% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Down 0.3 %

Pfizer stock traded down $0.08 during mid-day trading on Tuesday, hitting $26.16. The company had a trading volume of 16,869,348 shares, compared to its average volume of 37,560,887. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. The stock’s 50 day moving average price is $28.84 and its two-hundred day moving average price is $28.67. The company has a market capitalization of $148.25 billion, a PE ratio of 35.32, a price-to-earnings-growth ratio of 0.85 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.17) EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.42%. Pfizer’s dividend payout ratio is 227.03%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein began coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.